WuXi Biologics (Cayman) (FRA:1FW2) Beneish M-Score: -2.18 (As of Jun. 27, 2026)


FRA:1FW2 WuXi Biologics (Cayman) Inc FRA:1FW2
99 GF Score
Price €3.73
GF Value €4.30
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Beneish M-Score?

WuXi Biologics (Cayman) FRA:1FW2 +1.09% 99 Beneish M-Score is -2.18 as of Jun. 27, 2026. GuruFocus rates FRA:1FW2 with a GF Score™ of 99/100 and a GF Value™ of €4.30 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, WuXi Biologics (Cayman) ranks worse than 56.2% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.18 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for WuXi Biologics (Cayman)'s Beneish M-Score or its related term are showing as below:

FRA:1FW2' s Beneish M-Score Range Over the Past 10 Years
Min: -2.79   Med: -2.11   Max: 1.84
Current: -2.18

During the past 12 years, the highest Beneish M-Score of WuXi Biologics (Cayman) was 1.84. The lowest was -2.79. And the median was -2.11.


WuXi Biologics (Cayman) Beneish M-Score Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Beneish M-Score Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.57 -2.38 -2.48 -2.79 -2.18

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.48 0.00 -2.79 0.00 -2.18

FRA:1FW2 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman) Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Beneish M-Score distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Beneish M-Score falls into.


FRA:1FW2
99GF Score
WuXi Biologics (Cayman) Inc FRA:1FW2
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of WuXi Biologics (Cayman) for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2004+0.528 * 0.891+0.404 * 1.0455+0.892 * 1.0786+0.115 * 1.0363
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9234+4.679 * -0.022491-0.327 * 0.8303
=-2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €983 Mil.
Revenue was €2,642 Mil.
Gross Profit was €1,215 Mil.
Total Current Assets was €3,411 Mil.
Total Assets was €7,723 Mil.
Property, Plant and Equipment(Net PPE) was €3,608 Mil.
Depreciation, Depletion and Amortization(DDA) was €176 Mil.
Selling, General, & Admin. Expense(SGA) was €280 Mil.
Total Current Liabilities was €1,007 Mil.
Long-Term Debt & Capital Lease Obligation was €224 Mil.
Net Income was €595 Mil.
Gross Profit was €0 Mil.
Cash Flow from Operations was €769 Mil.
Total Receivables was €759 Mil.
Revenue was €2,450 Mil.
Gross Profit was €1,004 Mil.
Total Current Assets was €3,092 Mil.
Total Assets was €7,474 Mil.
Property, Plant and Equipment(Net PPE) was €3,730 Mil.
Depreciation, Depletion and Amortization(DDA) was €188 Mil.
Selling, General, & Admin. Expense(SGA) was €282 Mil.
Total Current Liabilities was €1,131 Mil.
Long-Term Debt & Capital Lease Obligation was €304 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(982.759 / 2642.077) / (759.048 / 2449.624)
=0.371965 / 0.309863
=1.2004

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1003.548 / 2449.624) / (1214.762 / 2642.077)
=0.409674 / 0.459775
=0.891

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3411.459 + 3607.728) / 7723.338) / (1 - (3092.065 + 3729.831) / 7473.656)
=0.091172 / 0.087208
=1.0455

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2642.077 / 2449.624
=1.0786

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(188.497 / (188.497 + 3729.831)) / (175.627 / (175.627 + 3607.728))
=0.048106 / 0.046421
=1.0363

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(280.492 / 2642.077) / (281.634 / 2449.624)
=0.106163 / 0.11497
=0.9234

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((224.146 + 1007.306) / 7723.338) / ((304.422 + 1130.838) / 7473.656)
=0.159446 / 0.192043
=0.8303

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(595.145 - 0 - 768.848) / 7723.338
=-0.022491

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

WuXi Biologics (Cayman) has a M-score of -2.30 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.18 mean?
WuXi Biologics (Cayman) (FRA:1FW2) has a Beneish M-Score of -2.18 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on WuXi Biologics (Cayman) and its competitors. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #467 out of 831 companies in the Biotechnology industry, placing it in the top 56.2%.
Is WuXi Biologics (Cayman)'s Beneish M-Score too high?
WuXi Biologics (Cayman)'s current Beneish M-Score is -2.18. Based on the distribution chart, WuXi Biologics (Cayman) ranks #467 out of 831 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #467 out of 831 companies for Beneish M-Score. This places WuXi Biologics (Cayman) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Beneish M-Score is -2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (FRA:1FW2) is currently considered Modestly Undervalued. The stock's GF Value™ is €4.30, compared to a current price of €3.73 — trading 13.4% below its estimated fair value. The current Beneish M-Score is -2.18. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For WuXi Biologics (Cayman) (FRA:1FW2), the current Beneish M-Score is -2.18 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (FRA:1FW2) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of €3.73 is trading 13.4% below its estimated GF Value™ of €4.30. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for FRA:1FW2:

  • Beneish M-Score: -2.18
  • GF Value™: €4.30 vs. price of €3.73 (13.4% below fair value)
  • GF Score™: 99/100 with 3 warning signs

No single metric tells the full story. See the FRA:1FW2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score

Get the complete analysis for FRA:1FW2

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.73
Price
€4.30
GF Value